Jupiter Neurosciences Teams with Catalent to Manufacture JOTROL for Parkinson's Disease Trial
Key Insights
Jupiter Neurosciences (search) has partnered with Catalent Pharma Solutions to produce JOTROL softgel capsules, a resveratrol-based therapeutic, for an upcoming Phase 2a (search) clinical trial in Parkinson's disease (search).
The manufacturing agreement includes production of both active and placebo batches using an optimized softgel formulation, leveraging Catalent's expertise in pharmaceutical manufacturing.
The Phase 2a (search) trial will assess JOTROL's safety, tolerability, and pharmacokinetics/pharmacodynamics in Parkinson's patients over a three-month study period.
Jupiter Neurosciences (search) Inc. has established a strategic manufacturing partnership with Catalent Pharma Solutions LLC to produce JOTROL softgel capsules for its upcoming Phase 2a (search) clinical trial targeting Parkinson's disease (search). The collaboration marks a significant step forward in advancing Jupiter's novel resveratrol-based therapeutic platform.
Manufacturing Partnership Details
The agreement tasks Catalent with manufacturing clinical batches of JOTROL using an optimized softgel formulation. The production scope encompasses both active drug and placebo capsules essential for the planned Parkinson's disease (search) study. This partnership leverages Catalent's established expertise in pharmaceutical manufacturing and their capability to meet precise production timelines.
Christer Rosén, Chairman and CEO of Jupiter Neurosciences (search), emphasized the strategic importance of the collaboration, stating, "Securing an experienced CDMO leader like Catalent is a critical step as we advance JOTROL into clinical development for Parkinson's disease (search)." He further highlighted that "Catalent's industry-leading expertise in pharmaceutical manufacturing and its ability to scale production efficiently according to a tight timeline will help us maintain momentum in our development program and support our goal of delivering innovative therapies to patients."
Upcoming Clinical Trial
The Phase 2a (search) clinical trial represents a crucial evaluation phase for JOTROL, focusing on three primary aspects:
- Safety assessment
- Tolerability profile
- Pharmacokinetics and pharmacodynamics (PK/PD) characteristics
The study is designed to span three months, during which Parkinson's disease (search) patients will receive the investigational treatment. This trial will provide essential data to guide the further development of JOTROL as a potential therapeutic option for Parkinson's disease patients.
JOTROL Platform Technology
JOTROL, Jupiter's proprietary therapeutic, is built on a patented resveratrol-based platform. Resveratrol, known for its potential neuroprotective properties, has been optimized in JOTROL's formulation to potentially address the underlying mechanisms of Parkinson's disease (search). The softgel capsule format has been specifically chosen to optimize drug delivery and patient compliance.